eli lilly glp 1 agonist FDA just approved orforglipron (Foundayo), Lilly's oral GLP-1 receptor for obesity. In the ATTAIN-1 phase 3 trial (n=3,127), published in the New England Journal of Medicine, patients on the highest Lilly is now pharma's top
Pay in 4 interest-free payments of $6.82 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4








-1775582746855.png&w=3840&q=75)
















